| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 19 | 2024 | 3869 | 0.960 |
Why?
|
| Immunotherapy, Adoptive | 10 | 2024 | 1763 | 0.660 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2020 | 1146 | 0.460 |
Why?
|
| Tissue and Organ Procurement | 1 | 2015 | 233 | 0.440 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2023 | 6550 | 0.420 |
Why?
|
| Genetic Therapy | 7 | 2024 | 1616 | 0.390 |
Why?
|
| Oncolytic Viruses | 2 | 2024 | 204 | 0.390 |
Why?
|
| Herpesvirus 4, Human | 7 | 2018 | 966 | 0.380 |
Why?
|
| Cell- and Tissue-Based Therapy | 3 | 2023 | 406 | 0.380 |
Why?
|
| Caspase 9 | 3 | 2015 | 189 | 0.340 |
Why?
|
| Stem Cells | 1 | 2015 | 1213 | 0.330 |
Why?
|
| Lymphoma, T-Cell | 2 | 2024 | 361 | 0.320 |
Why?
|
| Antigens, CD19 | 5 | 2024 | 577 | 0.320 |
Why?
|
| Neuroblastoma | 4 | 2023 | 686 | 0.320 |
Why?
|
| Ki-1 Antigen | 2 | 2020 | 182 | 0.310 |
Why?
|
| Hodgkin Disease | 4 | 2020 | 1429 | 0.310 |
Why?
|
| Drugs, Investigational | 2 | 2023 | 135 | 0.300 |
Why?
|
| Graft vs Host Disease | 6 | 2022 | 2638 | 0.300 |
Why?
|
| Lymphoma | 3 | 2023 | 1467 | 0.290 |
Why?
|
| Retroviridae | 4 | 2022 | 332 | 0.280 |
Why?
|
| Marketing | 1 | 2023 | 18 | 0.240 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2013 | 1016 | 0.230 |
Why?
|
| Neomycin | 2 | 2000 | 38 | 0.230 |
Why?
|
| Compassionate Use Trials | 1 | 2023 | 21 | 0.230 |
Why?
|
| Salvage Therapy | 3 | 2021 | 2054 | 0.220 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2018 | 1039 | 0.210 |
Why?
|
| Natural Killer T-Cells | 1 | 2023 | 124 | 0.200 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2018 | 489 | 0.200 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 105 | 0.190 |
Why?
|
| Lymphocyte Transfusion | 1 | 2021 | 175 | 0.190 |
Why?
|
| Interleukin-2 | 4 | 2005 | 842 | 0.180 |
Why?
|
| Antigens, Neoplasm | 3 | 2021 | 1506 | 0.180 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 280 | 0.180 |
Why?
|
| Receptor, ErbB-2 | 3 | 2020 | 2518 | 0.180 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 109 | 0.170 |
Why?
|
| Virus Replication | 1 | 2022 | 709 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 846 | 0.170 |
Why?
|
| Leukemia | 3 | 2022 | 1635 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 2 | 2018 | 895 | 0.160 |
Why?
|
| Anemia | 1 | 2024 | 689 | 0.160 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 29 | 0.150 |
Why?
|
| Transplantation, Homologous | 7 | 2022 | 2843 | 0.150 |
Why?
|
| DNA Viruses | 1 | 2017 | 48 | 0.150 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 341 | 0.150 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 1870 | 0.140 |
Why?
|
| Child | 15 | 2023 | 29154 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 10035 | 0.140 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 73 | 0.140 |
Why?
|
| Recurrence | 7 | 2022 | 4758 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2016 | 2390 | 0.130 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2015 | 69 | 0.130 |
Why?
|
| Adenoviridae | 5 | 2023 | 1459 | 0.130 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2017 | 387 | 0.130 |
Why?
|
| CD40 Ligand | 2 | 2005 | 115 | 0.130 |
Why?
|
| CD28 Antigens | 2 | 2017 | 202 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 1 | 2000 | 1581 | 0.130 |
Why?
|
| Cancer Vaccines | 3 | 2005 | 697 | 0.130 |
Why?
|
| Humans | 37 | 2024 | 261506 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 1555 | 0.110 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 125 | 0.110 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 1991 | 17 | 0.100 |
Why?
|
| Chemokines, C | 2 | 2002 | 10 | 0.100 |
Why?
|
| Transgenes | 1 | 2014 | 557 | 0.100 |
Why?
|
| Adolescent | 13 | 2021 | 31252 | 0.100 |
Why?
|
| Immunotherapy | 4 | 2023 | 3341 | 0.100 |
Why?
|
| Male | 23 | 2024 | 123000 | 0.100 |
Why?
|
| Sialoglycoproteins | 2 | 2002 | 151 | 0.100 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2011 | 87 | 0.100 |
Why?
|
| Lymphokines | 2 | 2002 | 272 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1048 | 0.090 |
Why?
|
| Treatment Outcome | 12 | 2020 | 32848 | 0.090 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 2979 | 0.090 |
Why?
|
| Young Adult | 8 | 2021 | 21445 | 0.090 |
Why?
|
| Organic Chemicals | 3 | 2015 | 113 | 0.090 |
Why?
|
| Female | 22 | 2024 | 141928 | 0.090 |
Why?
|
| Adult | 14 | 2022 | 77950 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 462 | 0.090 |
Why?
|
| Stem Cell Transplantation | 3 | 2020 | 1360 | 0.080 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 2138 | 0.080 |
Why?
|
| Genetic Vectors | 3 | 2022 | 1694 | 0.080 |
Why?
|
| Immunophenotyping | 4 | 2017 | 1681 | 0.080 |
Why?
|
| Lymphocyte Depletion | 2 | 2020 | 264 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 1249 | 0.080 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 482 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 8865 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 1294 | 0.080 |
Why?
|
| Transplantation, Autologous | 3 | 2020 | 1914 | 0.070 |
Why?
|
| Gene Transfer Techniques | 3 | 2011 | 716 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 5061 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2017 | 1797 | 0.070 |
Why?
|
| Neoplasms | 2 | 2023 | 15193 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2000 | 5178 | 0.070 |
Why?
|
| Middle Aged | 12 | 2021 | 86204 | 0.070 |
Why?
|
| Imidazoles | 1 | 1991 | 999 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 7789 | 0.070 |
Why?
|
| Cell Line | 3 | 2022 | 5114 | 0.060 |
Why?
|
| Leukemia, B-Cell | 1 | 2005 | 117 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2016 | 2292 | 0.060 |
Why?
|
| Sarcoma | 1 | 2015 | 1725 | 0.060 |
Why?
|
| Software | 1 | 1991 | 1321 | 0.060 |
Why?
|
| Child, Preschool | 7 | 2018 | 16273 | 0.060 |
Why?
|
| Remission Induction | 3 | 2020 | 3569 | 0.060 |
Why?
|
| Regenerative Medicine | 1 | 2023 | 49 | 0.060 |
Why?
|
| Cytokines | 3 | 2023 | 2809 | 0.060 |
Why?
|
| Industry | 1 | 2003 | 53 | 0.060 |
Why?
|
| Biotechnology | 1 | 2003 | 63 | 0.060 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 2864 | 0.050 |
Why?
|
| Albumins | 1 | 2024 | 258 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 208 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 2576 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2023 | 288 | 0.050 |
Why?
|
| Quality Control | 1 | 2003 | 457 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2003 | 332 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 6915 | 0.050 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 107 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2023 | 675 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2023 | 560 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 4849 | 0.050 |
Why?
|
| Aged | 7 | 2021 | 70117 | 0.050 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 107 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 2796 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2024 | 1021 | 0.040 |
Why?
|
| Biological Products | 1 | 2003 | 274 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 709 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 650 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1819 | 0.040 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 2238 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2023 | 1234 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 685 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 201 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 604 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2024 | 1996 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 181 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2330 | 0.040 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 81 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2021 | 769 | 0.040 |
Why?
|
| BK Virus | 1 | 2017 | 123 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 486 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2017 | 269 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 15862 | 0.030 |
Why?
|
| Vidarabine | 1 | 2020 | 1341 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1998 | 974 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 35 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 2173 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2017 | 279 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 249 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 446 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 14889 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 2014 | 135 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 100 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 3001 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 1489 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 856 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 833 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 366 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2020 | 2358 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 3719 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 3443 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 246 | 0.030 |
Why?
|
| Microcomputers | 1 | 1991 | 36 | 0.030 |
Why?
|
| Mice | 2 | 2023 | 34495 | 0.030 |
Why?
|
| Drug Incompatibility | 1 | 1991 | 2 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1290 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 14551 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1991 | 84 | 0.020 |
Why?
|
| Drug Compounding | 1 | 1991 | 70 | 0.020 |
Why?
|
| Solutions | 1 | 1991 | 104 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1217 | 0.020 |
Why?
|
| Ondansetron | 1 | 1991 | 42 | 0.020 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 406 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 305 | 0.020 |
Why?
|
| Transduction, Genetic | 2 | 2002 | 475 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2014 | 398 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1991 | 220 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1991 | 585 | 0.020 |
Why?
|
| Prognosis | 2 | 2021 | 21713 | 0.020 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 482 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1991 | 467 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 4938 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2005 | 1033 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 3033 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1991 | 1382 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 59536 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 929 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 1487 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 7551 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 1991 | 884 | 0.020 |
Why?
|
| Time Factors | 2 | 2014 | 12926 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 6682 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 1688 | 0.020 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 14289 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2005 | 55 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2992 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 186 | 0.020 |
Why?
|
| United States | 1 | 2003 | 15433 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3570 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6207 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 212 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2005 | 314 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 5112 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 9244 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 5395 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2005 | 626 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 700 | 0.010 |
Why?
|
| Immune System | 1 | 2005 | 279 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2002 | 104 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 117 | 0.010 |
Why?
|
| Panniculitis | 1 | 2002 | 58 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 334 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 297 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2002 | 257 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 869 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2005 | 778 | 0.010 |
Why?
|
| Texas | 1 | 1991 | 6311 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 1385 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 37905 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 1021 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 7702 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1998 | 202 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 218 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 573 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 7591 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 904 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 1259 | 0.010 |
Why?
|
| Infant | 2 | 2002 | 13310 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 7226 | 0.010 |
Why?
|